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Abstract 
 
Since its first publication in 2003, the Gene Set Enrichment Analysis (GSEA) 
method, based on the Kolmogorov-Smirnov statistic, has been heavily used, 
modified, and also questioned.  Recently a simplified approach, using a one-
sample t-test score to assess enrichment and ignoring gene-gene 
correlations was proposed by Irizarry et al. 2009 as a serious contender.  The 
argument criticizes GSEA’s nonparametric nature and its use of an empirical 
null distribution as unnecessary and hard to compute. We refute these claims 
by careful consideration of the assumptions of the simplified method and its 
results, including a comparison with GSEA’s on a large benchmark set of 50 
datasets. Our results provide strong empirical evidence that gene-gene 
correlations cannot be ignored due to the significant variance inflation they 
produced on the enrichment scores and should be taken into account when 
estimating gene set enrichment significance. In addition, we discuss the 
challenges that the complex correlation structure and multi-modality of gene 
sets pose more generally for gene set enrichment methods. 
 
Introduction 
 
The availability of global transcription profiling with microarrays in the mid 1990s made 
possible the analysis and interpretation of the activity of the entire transcriptome to 
provide insights into biological function and the mechanisms of disease. Early on, it 
became clear that focusing on long lists of differentially expressed genes gave limited 
understanding of underlying pathways and processes. Several approaches to consider 
testing for the over-representation of gene categories rather than genes were 
introduced by [1,2,3,4,5,6]. In [7] we introduced a knowledge-based approach analysis 
method, Gene Set Enrichment Analysis (GSEA) to address this problem. Briefly, this 
initial approach ranked genes by their differential expression between two phenotypes, 
used the Kolmogorov-Smirnov statistic to score the enrichment of an a priori defined 
sets of genes that share common biological function, chromosomal location or 
regulation, and evaluated the significance of the score using an empirical permutation 
test correcting for multiple hypothesis testing.  Thus, GSEA provided a prioritized list of 
sets of genes for hypothesis generation and further study. In this first application we 
identified a set of genes involved in oxidative phosphorylation with reduced expression 
in diabetic patients.  None of these genes were down-regulated by more than 20%, but 
as a group their coordinate down-regulation was significant and, together with 
subsequent work, lead to a better understanding of the regulation of the oxidative 
phosphorylation pathway [8,9] as many its components turned out to be controlled by 
the PCG1A transcription factor, which was itself down-regulated in diabetic patients.  
  
As soon as this original version of GSEA appeared, objections were raised to the 
approach [10], some of which were immediately refuted in [11], and the rest were met 
by our subsequent improvement of the GSEA methodology. In Subramanian and 
Tamayo et al. [12] we introduced a version of GSEA that used a correlation-weighted 
Kolmogorov-Smirnov statistic, an improved enrichment normalization procedure, and an 
FDR-based estimate of significance that collectively made GSEA appreciably more 
sensitive, more general, and more robust. As a result of these improvements, and the 
public availability of the software and companion Molecular Signatures Database 
(MSigDB) [www.broadinstitute.org/gsea], GSEA became a widely used method and was 
applied to numerous problems across many application domains. Notably, since the 
original release of the software and database in 2005, the number of GSEA user 
registrations has grown to over 33,000, and the method used and cited in more than 
3,100 scientific publications. GSEA and other gene set analysis methods have also 
motivated the development of general statistical methodologies for large-scale inference 
for “sets” of variables [13,14]. 
 
The specific knowledge-based approach pioneered by GSEA is now standard practice 
in the analysis of gene expression data and inspired the development of a large and 
growing family of conceptually similar methods. For example, Huang et al. [15] identified 
at least 68 different gene set enrichment methods in their survey. A family of popular 
methods estimate the over-representation of Gene Ontology (GO) annotations using a 
hyper-geometric statistic or Fisher’s exact test (e.g., GoMiner [16], FatiGO [17], 
GoSurfer [18], EasyGo [19], David [20]). These methods restrict consideration to the 
“top” of the list, and may miss more subtle signals.  They also assume gene 
independence and thus produce overly optimistic results [15,21,22,23,24,25].  In 
addition, several improvements to gene set enrichment analysis itself have been 
proposed.  These include those used in [26], GSA [27], SAFE [28], Catmap [29], 
ErmineJ [30], and SAM-GS [31], and PROPA [32].  They employ alternative ranking 
metrics, enrichment statistics, and several variations on significance estimation 
schemes. Notably, [33] demonstrates the difficulty of finding a single, optimal statistic 
due to the complexity, heterogeneity and multi-modal distribution of the expression 
levels of genes within gene sets. Other somewhat more sophisticated methods (e.g., 
FunNet [34], PARADIGM [35], COFECO [36]), take a network-based approach, but 
restrict the analysis to processes where a deeper understanding of gene-gene 
interactions is already available. The primary advantages of GSEA are that it only 
requires gene set membership information to compute enrichment scores, considers the 
entire ranked list of genes, and maintains the gene-gene dependency that reflects real 
biology. This yields a good compromise between sensitivity, performance and 
applicability. 
 
Recently, Irizarry et al. [37] in their “Gene Set Enrichment Made Simple” article 
proposed a “simpler” approach to gene set expression analysis assuming gene 
independence and using a one-sample t-test to estimate enrichment. Here we will refer 
to their method as SEA (Simpler Enrichment Analysis). The rationale for SEA is based 
on their perception that that gene independence is a reasonable simplifying assumption 
and thus simpler parametric approaches to gene set analysis have been ignored. Both 
of these assumptions disregard a large body of literature where many authors have 
already introduced “simple” parametric methods for gene set analysis [38,39,40,41,42]. 
Many researchers have demonstrated the unrealistic nature and limitations of the gene 
independence assumption [21,22,23,24,25,43]. In addition, they criticized GSEA for its 
use of an empirical null distribution, which they argue is unnecessary and hard to 
compute; and for using a non-parametric weighted statistic that they believe inherits the 
lack of sensitivity of the original Kolmogorov-Smirnov statistic. The paper concludes by 
proposing SEA as a serious contender and argues against the use of GSEA in any of its 
forms.  
 
The aim of this paper is twofold. First, we present the SEA approach and contrast it with 
GSEA using the statistical framework of [43]. We then carefully consider Irizarry et al.’s 
[37] criticism of GSEA and refute their claims by systematically comparing SEA and 
GSEA on a large benchmark set of 50 datasets. We show, in agreement with earlier 
observations, that the gene independence assumption is not realistic because gene 
correlations are non-trivial and produce a substantial amount of variance inflation in the 
global statistic that in turn produces a large number of false positives results. Second, 
we discuss the challenges that the complex correlation structure and multi-modality of 
gene sets pose for gene set enrichment methods in general and propose that future 
progress in gene set analysis will result from improving the resolution of the gene sets 
and better ways to model the complex gene set correlation structure. 
 
Review of SEA and GSEA 
 
Here we review first the SEA approach proposed in [37] and then the GSEA approach 
proposed in [12] using the statistical framework of Barry et al. 2008 [43]. Several other 
valuable and complementary statistical frameworks for gene set analysis have been 
introduced in recent years [13,25,44,45,46].  
 
First we will define the quantities relevant for the analysis: the input gene expression 
dataset X corresponds to N genes and M samples and contains gene expression 
profiles xij, where i indicates a specific gene (row) and j a specific column (sample). The 
relevant phenotype of interest is defined as a vector Y of M binary values categorizing 
the sample in two groups (Y0, Y1). The gene sets are represented as gk.,where k runs 
from 1 to K, the maximum number of gene sets. We define a gene set enrichment 
method as a two-stage procedure incorporating i) a local test statistic si (xi•,Y )  that 
measures the association between a gene expression profile ( xi• ) and the phenotype 
(Y ); ii) a global test statistic Si  to assess the degree of the gene set’s enrichment, and 
iii) a specific null hypothesis and error rate controlling procedure to assess statistical 
significance and provide a final sorted gene set enrichment result list. The global 
statistic can be either a parametric or non-parametric function of the local test statistics 
corresponding to the gene set in question (“self-contained” statistic) and potentially all 
other genes (the complement or “competitive” statistic); 
 
The SEA method uses as local test statistic a two-sample t-test statistic ti that quantifies 
the magnitude of differential gene expression for each gene, 
 
  si (xi•,Y ) = ti= 
E(xij | j !Y0 )" E(xij | j !Y1)
# 2 (xij | j !Y0 )+# 2 (xij | j !Y1)
 (1) 
 
where the expected values and standard deviations (! ) are computed in each 
phenotypic class (Y0 /Y1 ). The SEA method can also be used with modified versions of 
this score [47] or with a signal to noise ratio as is used in GSEA. SEA’s global test 
statistic is a one-sample t-test  (z-score) that is used to estimate the “enrichment” of the 
entire gene set, 
 Szk = nk E(ti | i !gk ) = nk
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The SEA method assumes that these global statistics are independent and identically 
distributed (gene-independence), proposes a theoretical normal-theory null hypothesis, 
 
 Ho
SEA,  z :S1z ,S2z ,S3z ,...,SKz   are i.i.d and Skz ~ N(0,1),  (3) 
 
and estimates FDR q-values following the methodology of Storey 2002 [48]. Realizing 
that this global statistic only detects changes in location and fails to detect other more 
complex types of differential gene set behavior, the SEA method adds a second χ2 
global statistic, 
 Sg!
2
=
ti " E(ti )( )
2
i#gk
$ " (nk "1)
2(nk "1)
,  (4) 
 
and, as in the case of the z-score, an associated normal-theory null hypothesis, 
 
 H
o
SEA, !2 :S1!
2 ,S2!
2 ,S3!
2 ,...,SK!
2   are i.i.d and Sk!
2 ~ N(0,1),  (5) 
 
with the FDR computed in the same way as for the z-score. The SEA method is 
therefore based on the assumption that gene-gene correlations and gene set overlaps 
have negligible effects and therefore both global statistics (z-score and χ2) are 
independent and identically distributed under normal-theory null hypotheses H
o
SEA, z and 
H
o
SEA, !2 . The SEA null hypotheses are instances of the gene-sampling “Class 1” null 
hypothesis of [43]. We will say more about the applicability of this assumption to real 
datasets in the next section below. 
 
Before concluding our review of the SEA method, we point out that the second global 
statistic ironically renders SEA as less “simple,” since the potential user now has to 
consider two sets of results and their corresponding FDRs. Moreover, no formal 
procedure is specified by SEA in order to produce a final single list of results. Instead, 
the authors suggest choosing high scoring gene sets according to either one of the two 
global statistics. 
 
The GSEA method uses a signal to noise ratio as its local test statistic, 
   si (xi•,Y ) = 
E(xij | j !Y0 )" E(xij | j !Y1)
#$ (xij | j !Y0 )+ #$ (xij | j !Y1)  
(6) 
 
Where !" are the intra-class standard deviations thresholded from below at 20% of the 
class means, 
 
 !" (xij | j #Y*) =
" (xij | j #Y*)                if    " (xij | j #Y*)  $   0.20 % E(xij | j #Y*)
0.20 % E(xij | j #Y*)     if    " (xij | j #Y*)  <   0.20 % E(xij | j #Y*)
&
'
(
)(
 (7) 
 
GSEA uses a weighted Kolmogorov-Smirnov global statistic to assess gene set 
enrichment, 
 SkGSEA= sup
i=1,...,N
Figk − Figk( );        Figk =
sh
α Ih
h=1
i
∑
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α Ih
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N
∑
;        Figk =
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i
∑
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An important fact, not often appreciated, is that this global statistic is weighted using a 
power of the local statistic sh
! (typically with ! =1) and it is therefore much more 
sensitive to differences at the top and bottom of the gene list than the standard 
Kolmogorov-Smirnov statistic. Because this statistic cannot be expressed as a simple 
function of the local statistic, it posses challenges to formal analysis based on 
parametric modeling. 
 
The global statistics SkGSEA  depend on size of gene set and therefore are not identically 
distributed. GSEA addresses this issue by normalizing SkGSEA  values to factor out the 
intrinsic gene set size dependence. The relevant normalization is a change of scale 
using the expected value of the positive (negative) null distribution statistic induced by 
sample permutation, 
 
 !k
GSEA =
SkGSEA
E(SkGSEA | SkGSEA " 0)
    if   SkGSEA " 0
SkGSEA
E(SkGSEA | SkGSEA < 0)
   if   SkGSEA < 0
#
$
%
%
&
%
%
, (9) 
 
This rescaling is motivated by the asymptotic behavior of the Kolmogorov-Smirnov 
statistic (for details see supplementary information in [12]). This normalization effectively 
puts the gene set enrichment scores on the same scale analogous to how the 
factor nk does it for the SEA z-score.  This makes it possible to define a null distribution 
for the GSEA global statistics assuming a null distributionF0perm  induced by sample 
permutation, 
 
 Ho
GSEA, :!1GSEA ,!2GSEA ,!3GSEA ,...,!KGSEA  are identically distributed and !kGSEA ~ F0perm . (10) 
The null distribution F0perm  corresponds to the Class 2 type subject-sampling null 
hypothesis of [43].  
 
Our review of both methods clearly shows that SEA and GSEA differ in two important 
aspects: the choice of global statistics (z-score combined with ! 2  vs. weighted 
Kolmogorov-Smirnov) and the specific type of null hypothesis being assumed: gene-
sampling/Class 1 vs. subject-sampling/Class 2. 
 
The authors of SEA apply the method to the handful of examples used to introduce 
GSEA in [12] and make the following claims in favor of the gene independence 
hypothesis and against GSEA: 
(i) Differential gene expression scores can be assumed to be both independent 
and normally distributed. 
(ii) As a consequence of (i), the simpler gene set enrichment method (SEA) 
based on a one-sample t-test can effectively assess gene set enrichment in generic 
datasets. When SEA fails to find relevant gene sets it can be “fixed” by applying a 
second simple statistic (χ2).  
(iii) GSEA is computationally unnecessarily complicated. The complexity of using 
empirical null distributions in GSEA can be avoided by using theoretical (normal) null 
distributions. Moreover, the gene-gene independence assumption allows the adjustment 
for multiple hypotheses by using independent hypotheses FDR q-values [49];  
(iv) SEA is faster and simpler but equivalent to GSEA and therefore GSEA 
should not be used. SEA should be the basis of new methodologies for gene 
enrichment analysis;  
(v) GSEA is based on a Kolmogorov-Smirnov statistic, which is known to lack 
sensitivity and thus is rarely used. 
 
We will refute the authors’ claims below by studying the gene independence assumption 
behind the SEA method and by performing an empirical study of 50 datasets where we 
focus on the consequences of assuming gene independence. 
 
Empirical Analysis of SEA and GSEA. 
 
In their SEA approach Irizarry et al. [37] justify the gene-independence assumption 
based on the seemingly “straight” behavior of the gene expression scores in a handful 
of Q-Q plots (Figure 3, Irizarry et al. [37]) and conclude that “Barring a few outliers, 
which are likely associated to differentially expressed genes, the assumption appears 
appropriate in all datasets.” We believe this is an over-simplification and that the gene 
independence assumption is not appropriate in general. Here we present the results of 
an empirical study to systematically evaluate SEA and GSEA and assess the effect of 
the gene independence assumption in a representative benchmark set of 50 expression 
datasets, including some from the GSEA paper [12], as well as many more from GEO 
(Gene Expression Omnibus), the InSilico DB database of datasets 
[http://insilico.ulb.ac.be] and others from the literature. The complete list of these 
publicly available datasets is included in Supplementary Table ST1. 
 
This benchmark set is much more comprehensive and representative of the universe of 
datasets that may be used in gene set enrichment analysis. Most of the datasets derive 
from more recently generated data than the original GSEA examples, contain 
expression levels for greater numbers of genes, and display a much larger variety of 
phenotypic distinctions. 
 
In order to perform our comparative analysis we ran implementations of GSEA and SEA 
on all 50 benchmark sets and computed the corresponding results tables, including 
enrichment scores, p- and q-values for each gene set. In order to make a fair 
comparison of both methods we computed the GSEA q-values using exactly the same 
procedure as in SEA (i.e., computing q-values using the nominal p-values as inputs to 
the q-value R function/package [49]). For SEA, in order to produce a single score per 
gene set, we generated both proposed scores (z-score and χ2) and chose the one with 
smaller p-value as was suggested in [37]. 
 
First we note that SEA uniformly produces many more significant gene sets than GSEA. 
For example in the Pancreas dataset [50], featured in Fig. 1B, GSEA produces 121 
significant gene sets, out of a total of 1,368, at the suggested threshold (q-value < 0.25). 
In contrast, SEA produces 570 significant gene sets at the most stringent threshold of q-
value < 0.05. This number is almost 5 times more than GSEA and accounts for 42% of 
the total number of gene sets. Similar remarkably large results sets are produced by 
SEA in other datasets. This overproduction of significant results is further exacerbated 
in newer more comprehensive datasets with larger numbers of genes and stronger 
gene-phenotype correlations. SEA produces are large number of significant sets many 
of which we suspect are false positives due to the assumption of gene-gene 
independence.  It is, therefore not surprising, that among the SEA sets we find many of 
the significant results produced by GSEA [12]. 
 
It is difficult to assess in more direct terms the specificity/sensitivity of each method and 
specifically the exact percentage of false positives in SEA results because in general we 
do not have validated “ground truth” results for any given dataset. However, in our study 
we will use the methodology of Gatti et al. 2010 [21] where for each benchmark dataset, 
besides the observed global statistics corresponding to the relevant phenotype, we 
produced results for 1,000 randomly permuted phenotypes. Because the phenotypes 
have been randomized there is no significant correlation structure between the class 
labels and the gene profiles but the gene-gene correlations are preserved. We will use 
the observed and random-permutation global statistics to perform two groups of 
analyses: i) a study of the amount of variance inflation and the ii) inflation of p-values. 
 
Variance Inflation. 
 
One of the effects of gene-gene correlations and dependency structure in microarray 
datasets is the increase of variance in the global statistics. For example the SEA null 
hypothesis assumes the global statistics are i.i.d. and normally distributed, 
 
 Ho
SEA, z :S1z ,S2z ,S3z ,...,SKz   are i.i.d and Skz ~ N(0,1). (11) 
 
 Barry et al 2008 [43] studied the effects of gene dependency and found that for a 
difference of means statistic, quite similar to the SEA z-score, and gene set sizes that 
are small compared with the length of the gene list, the true variance of the statistic will 
differ from that under the i.i.d. class 1 gene-sampling null by a “variance inflation” factor 
!  that can be approximated by, 
 ! = 1+ nk" zk( ),  (12) 
where ! zk  is the average correlation between the global statistic (z-score) inside a gene 
set. For global statistics that are linear functions of the local statistic, ! zk  can be 
approximated with !Xk , the average correlation between gene expression profiles of 
genes in a dataset. From eq. 12 it is evident that the variance inflation increases with 
the product of the average intra-gene set correlation with the size of the gene set. 
Therefore, a small number of positive correlations within a gene set can result in 
substantial variance inflation if the gene set is large enough. For SEA the assumption of 
gene independence implies !Xk = 0  and therefore a variance inflation of one.  Gatti et al. 
2010 [21] studied about 200 real datasets and found strong variance inflation effects, 
roughly in the range from 1 to 6, as a result of rather modest positive gene correlations. 
Their results demonstrated the importance of this effect and the unrealistic nature of the 
gene sampling (class 1 and SAE) null hypothesis. 
 
In order to further investigate this issue, we analyzed the variance of the distribution of 
SEA z-scores under 3 null distributions: sample/phenotype-sampling (class 2), gene-
sampling (class 1) and SEA (theoretical normal null). In order to produce histograms we 
computed z-scores generated by 1,000 permutations of the samples and 1,000 
permutations of the gene identifiers.  Figure 1 shows the histograms of z-scores for P53 
[12] and Pancreas [50] datasets from the benchmark set. 
 
The histograms of z-scores for 1,000 permutations of the samples (shown in grey in Fig. 
1) show clearly how the gene correlations noticeably increase the width of the 
distribution and consequently produce significant variance inflation. For example, in the 
P53 and Pancreas datasets the variance of the z-score distribution for the sample 
permutations are 2.9 and 4.12, respectively. In contrast the variances for the gene-
sampling distributions are 0.96 and 1.02, which are very close to the SEA null value of 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional insight can be obtained from the histograms of individual average gene set 
internal correlations and variance inflation as shown in Figure 2. The gene correlations 
are on average mostly positive and relatively small, e.g., in the range [0, 0.30] (Figs 2A 
and 2C), but their effect on variance inflation can be significant and equivalent to a few 
times the variance of the SEA null distribution as estimated by eq. 12 (Figs 2B and 2D).  
 
Because of the strong effects of the gene correlations on the global statistic distribution 
the sample/phenotype-sampling class 2 (GSEA) null hypothesis is a much more realistic 
representative of the situation found in real datasets where there is always a non-
negligible amount of gene correlations.   
 
p-value inflation. 
 
The variance inflation in the global SEA statistic presented in the previous section is not 
only of academic interest. It has deleterious consequences in the form of high rates of 
false positives and inflated p-values. In Figure 3 we show histograms of p- and q-values 
for SEA and GSEA applied to the P53 (Fig 3A) and Pancreas datasets (Fig 3B) for 1000 
random permutations of their phenotype labels. Recall that these permutations are 
performed to eliminate, to the extent possible, the biological differences between the 
two resulting groups.  SEA produces a spurious over-population of low p-values that 
can be seen as a spike on the left side of the histogram in panel I of both Fig. 3A and 
Fig. 3B. These spikes include at least about 15% of all gene sets against the P53 
dataset and about 20% of all gene sets against the Pancreas dataset.  
A B 
Figure 1. Histograms of z-scores for 1,000 permutations of the samples (grey) and gene 
identifiers  (black), and the SEA null distribution N(0, 1) for the A) P53 and B) Pancreas 
datasets. The legend also shows the mean and variance of the distributions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The over-population of low p-values translates into a significant number of gene sets 
with low q-values (panel II of Figs. 3A and 3B). Using a q-value threshold of 0.05 this 
spurious population includes 11.5% of all gene sets against the P53 dataset and 20.1% 
of all gene sets against the Pancreas dataset. In contrast GSEA produces a practically 
flat histogram of p-values and no significant numbers of gene sets with low q-values as 
expected (Figs. 3A and 3B, panels III-IV). In this case, for example, the number of gene 
sets with q-values less than 0.05 is only 0.0248% for the P53 dataset and practically 
zero for the Pancreas dataset. Thus we see that SEA produces many significant gene 
sets in the absence of a biological signal as a consequence of ignoring gene-gene 
correlations.  This is a major drawback of the method. 
 
In Figure 4 and Table ST3 we summarize the randomized phenotype results for the 
entire benchmark set by showing the percentage of gene sets with q-values less than 
0.05 and 0.25 by SEA and GSEA. SEA uniformly produces a large number of false 
positives regardless of the choice of FDR threshold. To further demonstrate that this 
inflationary effect is indeed produced by the gene-gene correlations we used the same 
1,000 randomly permuted phenotypes as before, but we also randomly permuted the 
gene identifiers effectively destroying the gene-gene correlations. In this case, SEA 
shows similar behavior to GSEA and neither shows inflation of p-values (Fig. 5 A-B). 
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Figure 2. Histograms of gene correlations and estimated variance inflation for the P53 (A 
and B) and Pancreas datasets (C and D).  
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Figure 3. Histograms f p-values and q-values obtained by running SEA and GSEA on 1,000 
randomly permuted phenotypes in the P53 dataset (A) and the Pancreas dataset (B). The y-axis 
shows the percentage of gene sets results. 
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Figure 4. Percentage of gene sets with FDR less than 0.05 and 0.25 using SEA and GSEA in 
1,000 permutations of the phenotype labels for each dataset in the benchmark set. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above analysis convincingly demonstrates that ignoring gene-gene correlations and 
using the class 1(gene sampling) theoretical null distribution [13] have very negative 
consequences on the final results of SEA, and in fact on any enrichment method that 
assumes gene-gene independence. These results are very similar to those obtained by 
Gatti et al. 2010 [21] using different data sets and a similar, but different, statistic. 
 
All these results cast doubt on the validity of Irizarry et al.’s claims (i)-(iv) above. 
 
The complexity of gene score distributions in gene sets. 
 
The heterogeneous distribution of the expression of genes in gene sets poses a 
technical challenge to properly define enrichment scores. This derives from the fact that 
most gene sets are noisy and imperfect, or too context-dependent to be modeled with a 
simple assumption or statistic. Sometimes the genes sets are derived from generic 
“textbook” descriptions of a biological process, e.g., Biocarta pathways or GO 
ontologies, and thus have little relevance to coordinately expressed components of 
these pathways. In other cases, they are defined in a specific cellular context different 
from the one in which an investigator wishes to assess enrichment or they are a mixture 
of multiple biological processes that may not occur coherently in any single biological 
sample. For all these reasons, the distribution of gene scores displays rather complex 
multi-modal behavior and this it turn makes it difficult to define a single enrichment 
score that will work well across gene sets and datasets. 
 
Examples of this complex behavior are illustrated in Figure 6, where the behavior of 
three selected gene sets is shown across three of the benchmark datasets. The 
Figure 5. Histograms of p-values and q-values obtained by running SEA and GSEA on 1,000 
randomly permuted phenotypes and randomized gene identifiers for the P53 dataset (A) and the 
Pancreas dataset (B). In contrast with Fig 3 here the gene identifiers have also been randomized 
(gene-gene correlations not preserved). The y-axis shows the percentage of gene sets results.  
 
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
16
20
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
16
20
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.2 0.4 0.6 0.8 1.0
0
10
-
20
30
40
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0
10
20
30
40
P53 Dataset - Histograms of p- and q-values for
Randomized Phenotypes and Randomized Gene Identifiers
Pancreas Dataset - Histograms of p- and q-values for
Randomized Phenotypes and Randomized Gene Identifiers
A
B
SEA
GSEA
SEA
GSEA
I II
III IV
I II
III IV
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
16
20
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
16
20
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.2 0.4 0.6 0.8 1.0
0
10
-
20
30
40
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
p-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
4
8
12
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
q-values
%
 O
f T
ot
al
 G
en
e 
S
et
s
0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0
10
20
30
40
P53 Dataset - Histograms of p- and q-values for
Randomized Phenotypes and Randomized Gene Identifiers
Pancreas Dataset - Histograms of p- and q-values for
Randomized Phenotypes and Randomized Gene Identifiers
A
B
SEA
GSEA
SEA
GSEA
I II
III IV
I II
III IV
different panels illustrate the complex multi-modal behavior of gene sets that may occur. 
We note that in panels I, III, V and IX, a relatively high enrichment score of the gene set 
is produced by a subset of the genes, rather than the entire gene set. The genes 
responsible for the enrichment appear at either the top or bottom of the ranked gene list 
and are representatives of relevant biological processes that are indeed enriched in the 
studied phenotype. These examples are typical and show the complexities in modeling 
that gene set enrichment analyses encounter in practice. They also explain why it is 
difficult to describe the behavior of gene sets analytically and why overly simplistic 
assumptions such as those used in [37] are not likely to work.  By taking these 
complexities into account, one can better appreciate the motivation for the weighted 
Kolmogorov-Smirnov statistic as a good compromise between expecting all or most 
genes to be coherent on one side, and overweighting one or a few genes and allowing 
them to dominate the score on the other. It provides a reasonable distribution-free, but 
empirically adaptable, way to deal with the limitations and idiosyncrasies of real life 
gene sets. It may not be the most powerful statistic for any given simplistic 
circumstance, but the modification we made in [12] of weighting by phenotype 
correlation is sensitive where it has to be and deals well with the behavior of real gene 
sets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
The SEA method justifies the gene independence assumption based on the apparent 
normality of the local statistics (Q-Q plots), and the assumption that because intra-gene 
set gene correlations do not impact significantly the distribution of the global statistics.  
These assumptions are not supported by our empirical results. The strong effect of 
gene-gene correlations is well known and the need to take into account this 
Ribosomal
Proteins
Gene Set
(MSigDB v2.5)
MYOD NIH3T3
Gene Set
Genes up-regulated at
24 hours in NIH 3T3
cells following
transduction with MyoD 
(MSigDB v2.5)
Hinata NFKB UP
Gene Set
Genes up-regulated by
NF-kappa B  
(MSigDB v2.5)
Medulloblastoma Histology Dataset SNF5 Dataset PANCREAS Dataset
I
IV
VII
II
V
VIII
III
VI
IX
Figure 6. GSEA individual gene set enrichment plots: examples of top scoring gene sets that 
display complex behavior. 
dependency structure as part of gene set analysis has been well documented 
[22,23,24,25]. Of special note is the study of Gatti et al. [21] who performed a large 
empirical study of 200 datasets in their suggestively titled article “Heading Down the 
Wrong Pathway: on the Influence of Correlation within Gene Sets” and also 
demonstrated the practical impact of strong gene-gene correlations patterns and 
strongly criticized the use of the gene independence assumption.  
 
One limitation of the SEA study [37] is that they evaluated their method, and obtained 
their conclusions, in only a handful of datasets, namely the examples from the GSEA 
paper [12]. Those datasets were good examples to illustrate the use of the recently 
revised GSEA method at that time, but they do not constitute a comprehensive 
benchmark to systematically study the properties of a new method or to perform a 
comparison between competing methods. The collection of gene sets they used 
(MSigDB in 2005) is also relatively small (522 gene sets) compared with later releases 
of the same collection (e.g. 1,893 gene sets in MSigDB v2.5) where the overlap 
between gene sets is more significant.  
 
The authors of SEA also criticized the use of the Kolmogorov-Smirnov statistic in GSEA 
based on their view that it lacks sensitivity and is rarely used (their claim (v) above). 
However they failed to appreciate the fact that the weighted version used in GSEA is 
not the standard Kolmogorov-Smirnov statistic and was developed specifically to be 
more sensitive to differences in the tails of the distribution. Non-parametric statistics 
based on empirical cumulative distribution functions are the basis of new and powerful 
“goodness of fit” tests [51].  
 
Irizarry et al. [37] also listed as one of the motivations for SEA the fact that GSEA is 
slow and hard to compute (claims (iii) and (iv)). In Table 1 we show typical CPU 
execution times (Mac book Pro 8.3) for SEA and GSEA applied to two benchmark 
datasets (P53 and Pancreas). As seen in the table, SEA is indeed faster than GSEA 
because it avoids the generation of an empirical null distribution. However, a typical 
GSEA run takes only about 7 minutes and for almost all users this is an acceptable 
running time.  Moreover, SEA may be faster but this speed up comes at the high cost of 
large numbers of false positives as described above. 
 
Table 1. Typical CPU execution times for SEA and GSEA in the P53 and Pancreas 
datasets (Mac Book Pro 8,3).  
Method P53 Dataset Pancreas Dataset 
SEA (R implementation) 12.32 secs. 11.35 secs. 
GSEA (desktop application) 420 secs. 444 secs. 
 
 
Conclusions. 
 
We have shown strong empirical evidence that gene-gene correlations cannot be 
ignored and should be taken into account by gene set enrichment methods. Our results 
agree with the extensive literature providing theoretical or empirical evidence against 
the gene independence assumption [22,23,24,25] and counter the chief assumption of 
SEA [37].  
 
We benchmarked SEA against GSEA in a collection of 50 expression datasets. By 
randomizing phenotypes, we demonstrate that gene-gene correlations produce 
significant variance inflation in SEA results, which also exhibit very high false positive 
rates and significant numbers of inflated p- and q-values. Based on our empirical results 
we have refuted the claims of Irizarry et al. [37] and more broadly we recommend that 
methods that ignore gene-gene correlations, such as SEA, be avoided.  
 
Finally, we believe that the most important improvements that can be made to gene set 
enrichment methods are i) the improvement of gene set databases, like the MSigDB, so 
that their sets are less redundant and have more coherent behavior in actual biological 
samples; and ii) the development of more sophisticated methodologies that more 
accurately take into account or model gene correlations and the dependency structure 
in the data (i.e., the opposite of the SEA approach).  
 
By improving the resolution of gene sets we may overcome many of the limitations we 
have described above: noisiness, redundancy, multiple-process representation, poor 
specificity, etc. We are currently experimenting with the creation of a “hallmark” 
collection of gene sets in MSigDB that will contain more targeted representations of 
biological processes.  In addition, we are investigating the generation of coordinately 
expressed gene sets derived from the activation or repression of pathways in the 
laboratory. 
Our group, and many others, are currently engaged in efforts to improve gene set 
analysis through better modeling of the datasets’ correlation structure and by 
introducing additional information about the behavior of genes, (e.g., on a sample per 
sample basis and in supplementary datasets) as part of the gene set analysis. There 
are indeed many alternative approaches to pursue these goals and here we conclude 
by listing just a few: single-sample gene set enrichment [52,53,54], computational and 
theoretical methods for assessing size and effect of correlation in large-scale testing 
[22], eigenvalue-decomposition of covariance matrixes [55], rotation-based sampling 
[56], correlation-adjusted t-scores [57], modeling dependency among the genes within 
and across each gene set [58] and multiple testing procedures using dependency 
kernels [59]. Given the complexities of genomic data it is worthwhile to pursue new 
methodologies such as these; however, we should resist the temptation to over-simplify 
and remember the admonishments of Pearson and Tukey: 
“…it is not enough to know that a sample could have come from a normal population; we must be 
clear that it is at the same time improbable that it has come from a population differing so much 
from the normal as to invalidate the use of the ‘normal theory’ tests in further handling of the 
material.”                                                                                                        -- E. S. Pearson 
 “Far better an approximate answer to the right question, than the exact answer to the wrong 
question, which can always be made precise.”                       -- J. Tukey 
 
Methods 
 
Our implementation of GSEA is as described in Subramanian and Tamayo et al. [12]. 
The implementation of SEA followed the description given in Irizarry et al. [37]. We 
validated our implementation by exactly reproducing the t-test score and χ2 statistics 
from the result set of Irizarry et al. [37] in one of the datasets. 
 
We obtained the differential gene-expression scores using the signal to noise ratio as 
computed in GSEA and in SEA. We also normalized the differential gene expression 
scores by subtracting the median and dividing by the median absolute deviation as is 
done in SEA 
 
To perform the analyses of variance inflation and over-production of false positives and 
inflated p-values we followed the approach of Barry et al. 2008 [43] and Gatti et al. 2010 
[21]. For each dataset in the benchmark we randomized the phenotype labels 1,000 
times and ran both algorithms. We also computed enrichment scores by randomizing 
the gene labels. The p-values are computed using the areas under the empirical null 
histograms fro GSEA and areas under the normal distribution for SEA. The q-values 
were computed using the R function qvalue from package qvalue which implements the 
method described in Storey and Tibshirani [49]. 
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Supplementary Tables 
 
 Table ST1. List of Datasets for the Benchmark Set 
# Dataset Number of  
Samples 
Description Source 
1 Pancreas 36 Pancreatic cancer vs. normal pancreas. Abdollahi et al. 2007 [50] 
2 P53 50 NCI-60 cell lines with P53 mutant and wild type. Subramanian and Tamayo et al. 2005 [12] 
3 Gender 32 Male and Female samples. Subramanian and Tamayo et al. 2005 [12] 
4 Downs Syndrome 39 Downs syndrome samples vs. normal. GEO dataset GSE4119 
5 Cyclin D1 18 Cyclin D1 over-expression. Lamb et al. 2003 [60] 
6 Rhabdoid 48 Rahbdoid and other CNS tumors. Jagani et al. 2010 [61] 
7 Revlimid Response 16 Revlimid responders and non-responders in MDS. Ebert et al. 2008 [62] 
8 Metastasis 131 Primaries vs. metastasis. Wolfer et al. 2010 [63] 
9 Medulloblastoma monosomy 6 45 Medulloblastoma samples with monosomy 6. Pomeroy et al 2002 [64] 
10 Lung Cancer KRAS 53 Lung cancer cell lines with mutant and wt KRAS. Sos et al. 2010 
11 GSE6962 12 A549 lung cancer cells treated with Ionophores vs. contr. GEO dataset GSE6962 
12 GSE5462 116 Letrozole treated vs. untreated breast samples. GEO dataset GSE5462 
13 Yeoh et al dataset 20 ALL subtype E2A vs. ALL subtype TEL. Yeoh et al. 2002 [65] 
14 GSE14615 44 Continuous remission vs. relapse in T-ALL patients. GEO dataset GSE14615 
15 GSE7670 59 Tumor vs. adjacent normal in lung cancer samples. GEO dataset GSE7670 
16 GSE14642 40 Before vs. after exercise in females blood samples. GEO dataset  GSE14642  
17 GSE10961 18 Metachronous vs. synchronous liver metastasis. GEO dataset GSE10961 
18 GSE10281 36 Pre- vs. post-conventional treatment in breast cancer. GEO dataset GSE10281 
19 Lung cancer survival 62 Survivors vs. non-survivors in lung cancer. Subramanian and Tamayo et al. 2005 [12] 
20 GSE10174 26 Pre- vs. post-rasberry treatment in premalignant oral lesions. GEO dataset GSE10174 
21 GSE4475 24 Burkitt lymphoma and diffuse large B-cell lymphoma. GEO dataset GSE4475 
22 GDS2668 12 J1 embryonic cells late differentiation vs. control. GEO dataset GDS2668 
23 Ovarian 81 Platinum resistance vs. sensitive ovarian cancer samples. Dressman et al. 2007 [66] 
24 GDS495 27 VEGF-A treated vs. cntrl. umbilical cord(HUVEC) samples. GEO dataset GDS495 
25 GSE7562 12 PTEN RNAi knockouts vs. controls. GEO dataset GSE7562 
26 Melanoma 62 BRAF mutant vs. wt short-term melanoma samples. Lin et al. 2008 [67] 
27 GDS1306 18 MKK7D activated vs. controls in mouse heart samples. GEO dataset GDS1306 
28 GSE1413 19 mTOR inihibtion vs. controls in prostate mouse cells. GEO dataset GSE1413 
29 GSE9566 18 Astrocytes vs. neurons in mouse CNS samples. GEO dataset GSE9566 
30 Diabetes 34 Diabetics vs. normal samples. Mootha et al. 2003 [7] 
31 Mouse lung cancer 58 Mouse model of Kras2-mediated lung cancer vs. normal. Sweet-Cordero et al. 2005 [68] 
32 Trifluoperazine 22 Trifluoperazine treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
33 Pioglitazone 22 Pioglitazone treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
34 Vorinostat 24 Vorinostat treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
35 Rosiglitazone 24 Rosiglitazone treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
36 Troglitazone 24 Troglitazone treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
37 Fluphenazine 24 Fluphenazine treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
38 Genistein 24 Genistein treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
39 Alvespimycin 24 Alvespimycin treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
40 Acetylsalicylic 24 Acetylsalicylic acid treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
41 Alpha estradiol 24 Alpha estradiol treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
42 Nordihydroguaiaretic 24 Nordihydroguaiaretic acid treated vs. control samples. Connectivity Map 2.0 Lamb et al. 2006 [69] 
43 SHH 16 SHH induced vs. controls in mouse cerebellum samples. Zhao et al. 2002 [70] 
44 GSE7403 19 PDGF stimulated vs. controls in neuroblastoma cell lines. GEO dataset GSE7403 
45 GDS2025 24 Early vs. late MYC activation in pancreatic islet beta cells. GEO dataset GDS2025 
46 SNF5 18 SNF5 deficient vs. controls mouse samples. Isakoff et al. 2005 [71] 
47 HER2 21 HER2+ vs. HER2- breast cancer samples. Wang et al. 2005 [72] 
48 Leukemia 20 B- vs. T-Cell Leukemia samples. Ross et al. 2004 [73] 
49 Medulloblastoma histo. 34 Classic vs. desmoplastic medulloblastoma samples. Pomeroy et al. 2002 [64] 
50 E2F3 19 E2F3 induction vs. controls in breast epithelial cells. Bild et al. 2006 [74] 
Table ST2. Percentage of gene sets with q-values less than 0.05 and 0.25 produced by SEA 
and GSEA using 1000 randomized phenotypes. 
  SEA GSEA SEA GSEA 
# Dataset Percentage of 
gene sets with 
q-val < 0.05 
Percentage of 
gene sets with 
q-val < 0.05 
Percentage of 
gene sets with 
q-val < 0.25 
Percentage of 
gene sets with 
q-val < 0.25 
1 Pancreas 20.1 0.0248 46 1.49 
2 P53 11.5 0 31.6 0.688 
3 Gender 12.1 0 29.9 0.888 
4 Downs Syndrome 13.3 0 34.3 0.488 
5 Cyclin D1 5.68 0 17.5 0.0904 
6 Rhabdoid 19.8 0.005 46.1 1.01 
7 Revlimid Response 17.3 0 42.4 0.501 
8 Metastasis 18.8 0.0295 43.5 1.93 
9 Medulloblastoma monosomy 6 18.3 0.00641 43.6 2.28 
10 Lung Cancer KRAS 11.4 0 32 0.39 
11 GSE6962 1.79 0 6.89 0.207 
12 GSE5462 26.5 0.0596 54.4 3.09 
13 Yeoh et al dataset 2.85 0 9.42 0.0259 
14 GSE14615 22.4 0 49.1 1.41 
15 GSE7670 36.5 0.0132 66.4 3.25 
16 GSE14642 12.2 0 29.9 0.887 
17 GSE10961 27.4 0.0273 54.1 1.97 
18 GSE10281 21 0.0159 45.4 2.2 
19 Lung cancer survival 16.6 0 40.1 0.738 
20 GSE10174 19.4 0.014 43.7 1.53 
21 GSE4475 27.8 0.00337 56.6 1.49 
22 GDS2668 9.98 0 24.3 0.0466 
23 Ovarian  23.7 0.0184 49.6 2.02 
24 GDS495 6.42 0 17.4 0.0494 
25 GSE7562 4.69 0 15.1 1.11 
26 Melanoma 13.9 0.00528 34.7 1.01 
27 GDS1306 10.6 0.0108 29.9 0.736 
28 GSE1413 4.27 0 15.8 0.168 
29 GSE9566 19.3 0.148 44 5.2 
30 Diabetes 3.65 0 13.9 0.476 
31 Mouse lung cancer 5.37 0 18.5 0.0852 
32 Trifluoperazine  11.4 0 29.3 0.974 
33 Pioglitazone  6.47 0.0142 18.9 0.944 
34 Vorinostat  11 0 29.2 1.17 
35 Rosiglitazone  10.2 0 26.1 1.31 
36 Troglitazone  10.8 0 27.5 1.53 
37 Fluphenazine 11.2 0 28.4 1.18 
38 Genistein  10.7 0 26.9 1.28 
39 Alvespimycin  9.65 0.00987 25.1 0.954 
40 Acetylsalicylic  9.89 0.00578 25.9 0.938 
41 Alpha estradiol  10.7 0 27.1 1.22 
42 Nordihydroguaiaretic  10.1 0 26.4 0.885 
43 SHH  4.89 0.00174 15.7 0.187 
44 GSE7403 12.4 0.00825 30.8 0.283 
45 GDS2025 18 0.0553 39.2 3.4 
46 SNF5  19.6 0 45.8 0.522 
47 HER2  12.1 0.00176 32.3 0.795 
48 Leukemia 7.72 0 22 0.308 
49 Medulloblastoma histology 2.23 0 9.41 0.106 
 
